Health-related Quality of Life in Patients with Advanced Prostate Cancer: A Systematic Review

• In the current systematic review, over 800 articles were screened and 14 articles were included in the quantitative analysis. • Based on mostly phase III trials with a low risk of bias, beneficial effects on health-related quality of life (HRQOL) outcomes have been described for abiraterone acetate and docetaxel in the metastatic castration-sensitive prostate cancer setting, for apalutamide and enzalutamide in the nonmetastatic castration-resistant prostate cancer setting, and abiraterone acetate, enzalutamide, and radium-223 in the metastatic castration-resistant prostate cancer setting. • Efforts should be undertaken to optimize comparability between HRQOL outcomes based on different validated questionnaires as well as integration of supportive care regimens.